Now showing items 1-4 of 4

  • Alterations of the retinoblastoma gene in metastatic breast cancer 

    Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan; Lønning, Per Eystein (Springer, 2011-01-21)
    Germline mutations affecting the retinoblastoma gene (RB1) predispose to inherited retinoblastomas but also other malignancies, including breast cancer. While somatic RB1 mutations have been detected in different malignancies, ...
  • Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas 

    Klingen, Tor Audun; Chen, Ying; Suhrke, Pål; Stefansson, Ingunn; Gundersen, Marian D.; Akslen, Lars A. (BioMed Central, 2013-05-15)
    Background: The differential diagnosis between primary and secondary breast cancers might be difficult, especially in poorly differentiated tumors. Thyroid Transcription Factor-1 (TTF-1) has been regarded as a reliable ...
  • Oxidative stress in susceptibility to breast cancer: study in Spanish population 

    Rodrigues, Patricia; de Marco, Griselda; Furriol, Jessica; Mansego, Maria L.; Pineda-Alonso, Mónica; Gonzalez-Neira, Anna; Martin-Escudero, Juan C.; Benitez, Javier; Lluch, Ana; Chaves, Felipe J.; Eroles, Pilar (BioMed Central, 2014-11-21)
    Background: Alterations in the redox balance are involved in the origin, promotion and progression of cancer. Inter-individual differences in the oxidative stress regulation can explain a part of the variability in cancer ...
  • A randomized phase II pre-surgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor positive breast cancer 

    Serrano, Davide; Lazzeroni, Matteo; Gandini, Sara; Macis, Debora; Johansson, Harriet; Gjerde, Jennifer; Lien, Ernst Asbjørn; Feroce, Irene; Pruneri, Giancarlo; Sandri, Maria Teresa; Bassi, Fabio; Brenelli, Fabricio; Luini, Alberto; Cazzaniga, Massimiliano; Varricchio, Clara; Guerrieri-Gonzaga, Aliana; DeCensi, Andrea; Bonanni, Bernardo (BioMed Central, 2013-06-20)
    Introduction: We previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long ...